Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DynaCOMP

Financiado

Cerrado

Assessing compounds targeting DNA replication licensing complexes as anti tumor...

Assessing compounds targeting DNA replication licensing complexes as anti tumor agents Cancer is a major clinical, societal and economic burden worldwide and development of novel anti-cancer therapies constitutes a major investment of public and private funds. Despite intense research over decades however, which has... ver más

31/12/2018

UNIVERSITY OF PATR...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

PANEPISTIMIO PATRON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-31

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITY OF PATRAS

150.00K€ | Lider

PAGOS DEL MONCAYO

212.46K€ | Participante

Proyectos interesantes

BRCAstem

Medical Technol...

Data Science

225K€ Cerrado

GENECADD

Medical Technol...

Data Science

3M€ Cerrado

SAF2010-17935

Medical Technol...

Data Science

363K€ Cerrado

CANPLAST

Medical Technol...

Data Science

2M€ Cerrado

PID2021-125282OB-I00

Medical Technol...

Data Science

472K€ Cerrado

DEVOCAT

Medical Technol...

Data Science

100K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2017-06-16
Fecha Fin: 2018-12-31

Líder del proyecto

PANEPISTIMIO PATRON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is a major clinical, societal and economic burden worldwide and development of novel anti-cancer therapies constitutes a major investment of public and private funds. Despite intense research over decades however, which has led to a much improved understanding of cancer biology, cancer treatment remains a challenge. This is to a large extent due to the genetic heterogeneity of cancer and the ability of cancer cells to escape treatment by constantly undergoing further genetic alterations. During our ERC funded work, we have shown that aberrations in the DNA replication licensing pathway may contribute to the genome plasticity of cancer cells, and appear a common feature of cancer cells. They may however also constitute an Achilles foot, as cancer cells appear more dependent on negative regulators of the licensing system for survival. Cancer cells may therefore be more sensitive than normal cells to compounds targeting this control (inhibition of untimely licensing). We have identified compounds which target the DNA replication licensing inhibitor Geminin. The proposed PoC study will enable us to: - assess the efficacy and specificity of the identified compounds in cells and preclinical models and study their mechanism of action. - investigate the potential use of these compounds for studying cell cycle processes. - assess whether the functional imaging approaches developed under the mother ERC project, which quantify protein-protein interactions within living cells, may constitute a powerful tool for in-cell analysis of novel lead compounds. The project thus aims to characterize, protect and commercialize novel putative anti-tumor agents as well as the in-cell methods developed for their characterization.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores